Results 81 to 90 of about 2,223,573 (201)

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells

Cancer Treatment and Research Communications, 2020
Background: Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for first-line treatment of non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations.
Christy W.S. Tong, Mia M.X. Wu, Vivi W. Yan, William C.S. Cho, Kenneth K.W. To   +4 more
doaj   +1 more source

Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients

Technology in Cancer Research & Treatment, 2022
Introduction: Gefitinib is a selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) widely used in lung adenocarcinoma (LUAD) patients harboring sensitive EGFR mutations.
Junyong Zou MD, Huiyin Lan MD, Wei Li MD, Shuanshuan Xie MD, Zhongkai Tong MD, Xiaolian Song MD, Changhui Wang MD   +6 more
doaj   +1 more source

A lysosome‐targeted ultra‐sensitive viscosity probe for monitoring viscosity alterations during chemotherapy

Smart Molecules, EarlyView.
A novel chemosensing platform based on a molecular rotor architecture is established for specific, dynamic detection of lysosomal viscosity. The platform allows real‐time tracking of lysosomal viscosity fluctuations induced by various chemotherapeutic agents, highlighting its significant potential as a powerful tool for early cancer diagnostics and ...
Haoyang Song, Hui Bian, Lei Liu, Gahyeon Park, Bingqing Sun, Qiongzheng Hu, Juyoung Yoon   +6 more
wiley   +1 more source

Tp53 haploinsufficiency is involved in hotspot mutations and cytoskeletal remodeling in gefitinib-induced drug-resistant EGFR L858R -lung cancer mice

Cell Death Discovery, 2023
Tumor heterogeneity is the major factor for inducing drug resistance. p53 is the major defender to maintain genomic stability, which is a high proportion mutated in most of the cancer types.
Yi-Shiang Wang, Ming-Jer Young, Chia-Yu Liu, Yung-Ching Chen, Jan-Jong Hung   +4 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

, 2012
In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung ...
Koujirou Yamamoto, Kyoichi Kaira, Tadahiro Hashita, Hideaki Yashima, Takuya Araki, Tomonori Nakamura, Tohru Aomori, Koujirou Yamamoto,, Kimihiro Shimizu   +8 more
core   +1 more source

Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial–mesenchymal transition [PDF]

, 2012
Although cancers can be initially treated with the epidermal growth factor receptor (EGFR) inhibitor, gefitinib, continued gefitinib therapy does not benefit the survival of patients due to acquired resistance through EGFR mutations, c-MET amplification,
Kim, Hwang-Phill, Hwang-Phill Kim, Lee, Mi-Sook, Tae-You Kim, Lee, Jung Weon, Mi-Sook Lee, Jung Weon Lee, Kim, Tae-You, 이정원   +8 more
core   +1 more source

Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer

Anticancer drug conjugates may benefit from simultaneous action at two targets potentially overcoming the drawbacks of current cancer treatment, such as insufficient efficacy, high toxicity, and development of resistance. Compared to a combination of two
Raimund Niess (2003944), Matthias Gehringer (1692199), Franziska J. M. Kinnen (12240265), Darius P. Zlotos (1336923), Salma S. Hesse (12240268), Thales Kronenberger (4751028), Paula A. Witt-Enderby (2392666), Carine M. Abdelmalek (12240262), Stefan A. Laufer (128881), Mark Kudolo (5508644), Lars Zender (698425), Jenni Küblbeck (2110216), Zexi Hu (718831), Afsin Malik (12240271)   +13 more
core   +2 more sources